BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37740882)

  • 1. Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong S; Yu H; Wang H; Song J; Yan J
    Clin J Gastroenterol; 2023 Dec; 16(6):793-802. PubMed ID: 37740882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Long Y; Song X; Guan Y; Lan R; Huang Z; Li S; Zhang L
    J Gastroenterol Hepatol; 2023 Apr; 38(4):486-495. PubMed ID: 36516040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
    Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhuang BW; Li W; Xie XH; Hu HT; Lu MD; Xie XY
    Jpn J Clin Oncol; 2019 Sep; 49(9):845-855. PubMed ID: 31063184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
    Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Lyu N; Wang X; Li JB; Lai JF; Chen QF; Li SL; Deng HJ; He M; Mu LW; Zhao M
    J Clin Oncol; 2022 Feb; 40(5):468-480. PubMed ID: 34905388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis.
    Long GB; Xiao CW; Zhao XY; Zhang J; Li X
    Medicine (Baltimore); 2020 Jun; 99(26):e20745. PubMed ID: 32590750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    An C; Fu Y; Li W; Zuo M; Wu P
    Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Kim HJ; Lee SH; Shim HJ; Bang HJ; Cho SH; Chung IJ; Hwang EC; Hwang JE; Bae WK
    Front Oncol; 2023; 13():1265240. PubMed ID: 37881486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Han S; Choi HJ; Beom SH; Kim HR; Lee H; Lee JS; Lee HW; Park JY; Kim SU; Kim DY; Ahn SH; Han KH; Seong J; Won JY; Kim BK
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3123-3133. PubMed ID: 33893539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
    Regmi P; Hu HJ; Lv TR; Paudyal A; Sah RB; Ma WJ; Jin YW; Li FY
    Surg Oncol; 2021 Dec; 39():101663. PubMed ID: 34583091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX
    Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.
    Zheng K; Zhu X; Fu S; Cao G; Li WQ; Xu L; Chen H; Wu D; Yang R; Wang K; Liu W; Wang H; Bao Q; Liu M; Hao C; Shen L; Xing B; Wang X
    Radiology; 2022 May; 303(2):455-464. PubMed ID: 35103539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
    Saeki I; Yamasaki T; Maeda M; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
    PLoS One; 2019; 14(6):e0218136. PubMed ID: 31194789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma.
    Yan L; Lin J; Ke K; Wu Z; Huang J; Huang N; Yang W
    Transl Cancer Res; 2022 Jan; 11(1):99-112. PubMed ID: 35261888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
    Ahn YE; Suh SJ; Yim HJ; Seo YS; Yoon EL; Kim TH; Lee YS; Yim SY; Kim HR; Kang SH; Jung YK; Kim JH; Yeon JE; Um SH; Byun KS
    Gut Liver; 2021 Mar; 15(2):284-294. PubMed ID: 32307975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.